Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ziprasidone mesylate
Drug ID BADD_D02391
Description Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior.[A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.[A190525] Luckily, several treatment options for psychotic disorders have been introduced to market since the realization of chlorpromazine's antipsychotic properties in 1952.[A190525] Second generation antipsychotics (commonly referred to as atypical antipsychotics) include [clozapine], [quetiapine], [olanzapine], [aripiprazole] and [ziprasidone] among others, and are generally thought to be as efficacious as first generation antipsychotics but differ in their adverse effect profiles.[A190525,A190534] First generation antipsychotics are associated with extrapyramidal adverse effects while atypical antipsychotics are linked to weight gain, impaired glucose tolerance and metabolic syndrome.[A190534,A190537] Ziprasidone is used to treat schizophrenia and bipolar disorder.[A180748] It can effectively reduce the rate and time of relapses in schizophrenia, and can be used to treat manic episodes in bipolar disorder although the mechanism of action is unknown.[A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525]
Indications and Usage For the treatment of schizophrenia and related psychotic disorders.
Marketing Status Prescription; Discontinued
ATC Code N05AE04
DrugBank ID DB00246
KEGG ID D02100
MeSH ID C092292
PubChem ID 154068
TTD Drug ID D0R1JV
NDC Product Code 72266-160; 50090-4540; 0049-3920; 43598-848; 51662-1564; 68083-340; 0049-1203
Synonyms ziprasidone | ziprazidone | 5-(2-(4-(3-benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one | ziprasidone hydrochloride | CP 88059-01 | CP-88,059-1 | CP-88,059-01 | ziprasidone hydrochloride, monohydrate | Geodon | CP 88059 | CP-88,059
Chemical Information
Molecular Formula C22H25ClN4O4S2
CAS Registry Number 185021-64-1
SMILES CS(=O)(=O)O.C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Jaundice cholestatic09.01.01.005--Not Available
Keratitis06.04.02.002--
Ketosis14.01.01.001--Not Available
Laryngospasm22.04.02.002--
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Leukoplakia oral07.05.01.009--Not Available
Lymphadenopathy01.09.01.002--Not Available
Lymphocytosis01.02.01.003--Not Available
Lymphoedema24.09.01.001; 01.09.01.006--
Mania19.16.02.002--
Melaena24.07.02.013; 07.12.02.004--Not Available
Menorrhagia21.01.03.002--
Metrorrhagia21.01.01.006--Not Available
Monocytosis01.02.01.004--Not Available
Muscle twitching15.05.03.005--Not Available
Myalgia15.05.02.001--
Myocarditis02.04.03.001--
Myoclonus17.02.05.008--Not Available
Myopathy15.05.05.001--Not Available
Nausea07.01.07.001--
Neuroleptic malignant syndrome17.05.02.003; 12.03.01.003; 15.05.04.015; 08.05.01.005--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Nocturia20.02.03.001--Not Available
Nystagmus17.02.02.006; 06.05.02.006--
Oculogyric crisis17.01.03.002; 06.05.02.002--Not Available
The 5th Page    First    Pre   5 6 7 8    Next   Last    Total 8 Pages